Evidence map›Paper›PMID 29112723›Full record

ArticleHuman molecular genetics2018

In vitro and in vivo studies of the ALS-FTLD protein CHCHD10 reveal novel mitochondrial topology and protein interactions.

S R Burstein, F Valsecchi, H Kawamata, M Bourens, R Zeng, A Zuberi, T A Milner, S M Cloonan, C Lutz, A Barrientos and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 119 citations in OpenAlex.

  1. Article
  2. Frontotemporal dementia associated CHCHD10Cell death & disease · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Molecular machineries shaping the mitochondrial inner membrane.Nature reviews. Molecular cell biology · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Chchd10: A Novel Metabolic Sensor Modulating Adipose Tissue Homeostasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  17. Article
  18. Article
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

S R BursteinFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
F ValsecchiFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
H KawamataFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
M BourensDepartment of Neurology, Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
R ZengDepartment of Neurology, Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
A ZuberiThe Jackson Laboratories, ME 04609, USA.
T A MilnerFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
S M CloonanDivision of Pulmonary and Critical Care Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY 10065, USA.
C LutzThe Jackson Laboratories, ME 04609, USA.
A BarrientosDepartment of Neurology, Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
G ManfrediFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10065, USA.
Cornell University · USUniversity of Miami · USJackson Laboratory · USWeill Cornell Medicine · USRockefeller University · US

Funding

Mitochondrial Biogenesis in Health and DiseaseR35GM118141 · NIGMS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BARRIENTOS, ANTONI · 2016 to 2025
$8.9M
ULTRASTRUCTURAL INTERACTIONS OF OPIOIDS IN HIPPOCAMPUSR01DA008259 · NIDA · WEILL MEDICAL COLL OF CORNELL UNIV · PI MILNER, TERESA A · 1993 to 2019
$6.4M
Mitochondrial Iron metabolism in Chronic Obstructive Pulmonary DiseaseR00HL125899 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CLOONAN, SUZANNE M · 2017 to 2019
$747k
Mitochondrial Iron metabolism in Chronic Obstructive Pulmonary DiseaseK99HL125899 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI CLOONAN, SUZANNE M · 2015 to 2016
$285k
NHLBI NIH HHS K99 HL125899NHLBI NIH HHS R00 HL125899NIDA NIH HHS R01 DA008259NIGMS NIH HHS R35 GM118141
6 · The paper itself

Abstract

Mutations in coiled-coil-helix-coiled-coil-helix-domain containing 10 (CHCHD10), a mitochondrial twin CX9C protein whose function is still unknown, cause myopathy, motor neuron disease, frontotemporal dementia, and Parkinson's disease. Here, we investigate CHCHD10 topology and its protein interactome, as well as the effects of CHCHD10 depletion or expression of disease-associated mutations in wild-type cells. We find that CHCHD10 associates with membranes in the mitochondrial intermembrane space, where it interacts with a closely related protein, CHCHD2. Furthermore, both CHCHD10 and CHCHD2 interact with p32/GC1QR, a protein with various intra and extra-mitochondrial functions. CHCHD10 and CHCHD2 have short half-lives, suggesting regulatory rather than structural functions. Cell lines with CHCHD10 knockdown do not display bioenergetic defects, but, unexpectedly, accumulate excessive intramitochondrial iron. In mice, CHCHD10 is expressed in many tissues, most abundantly in heart, skeletal muscle, liver, and in specific CNS regions, notably the dopaminergic neurons of the substantia nigra and spinal cord neurons, which is consistent with the pathology associated with CHCHD10 mutations. Homozygote CHCHD10 knockout mice are viable, have no gross phenotypes, no bioenergetic defects or ultrastructural mitochondrial abnormalities in brain, heart or skeletal muscle, indicating that functional redundancy or compensatory mechanisms for CHCHD10 loss occur in vivo. Instead, cells expressing S59L or R15L mutant versions of CHCHD10, but not WT, have impaired mitochondrial energy metabolism. Taken together, the evidence obtained from our in vitro and in vivo studies suggest that CHCHD10 mutants cause disease through a gain of toxic function mechanism, rather than a loss of function.

Indexed as

Amyotrophic Lateral SclerosisAnimalsCarrier ProteinsDNA-Binding ProteinsFrontotemporal DementiaGenetic Association StudiesHEK293 CellsHeLa CellsHumansMiceMice, Inbred C57BLMice, KnockoutMitochondriaMitochondrial ProteinsModels, MolecularMutationC1QBP protein, humanCarrier ProteinsCHCHD10 protein, humanCHCHD2 protein, humanDNA-Binding ProteinsMitochondrial ProteinsTranscription Factors

Identifiers

PMID29112723
PMCPMC5886281
OpenAlexW2766046440

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.